The activity of gatifloxacin against 308 aerobes and 112 anaerobes isolated from bite wound infections was studied. Gatifloxacin was active at <0.016 g/ml against all 148 Pasteurella isolates (eight species and three subspecies) tested and all other aerobes tested, including Actinobacillus-Haemophilus spp., Eikenella corrodens, Neisseria weaveri, Weeksella zoohelcum, staphylococci, and streptococci. Fusobacteria were sometimes resistant. Gatifloxacin MICs at which 90% of the isolates were inhibited were 0.125 g/ml against Bacteroides tectum and Prevotella spp., 0.25 g/ml against Porphyromonas spp., and 0.5 g/ml against peptostreptococci.
Approximately 5 million Americans are bitten annually by animals (2, 7, 21, 25) , and many bites become infected with a wide variety of fastidious aerobic bacteria and anaerobic veterinary bacteria (1, 3, 4, 8, 15, 20, 25) . These unusual isolates are not included in published susceptibility testing surveys of newer antimicrobial compounds (9, 10) . A clinician must rely on published studies to guide both empirical and subsequent specific antimicrobial therapeutic choices.
Gatifloxacin (BMS-206584; AM-1155) is a new 8-methoxy fluoroquinolone [1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid) with R and S enantiomers that have identical pharmacokinetics after oral and intravenous administration and a broad spectrum of activity (5, 13, 14, 26) . In order to determine its activity against various pathogenic species, we compared the susceptibilities of 420 recent clinical bite wound isolates to gatifloxacin and five other fluoroquinolones.
The strains were previously isolated from bite wounds and identified by standard criteria (11, 12, 16, 17, 24) . The specific bite sources (n) were dogs (146), cats (208), humans (23) , and other (24) . Twelve bovine respiratory strains, especially Pasteurella haemolytica, were included for comparative purposes; 7 American Type Culture Collection (ATCC) strains and 6 control strains were also tested. The numbers and species of isolates tested are shown in Table 1 Susceptibility testing was performed by use of National Committee for Clinical Laboratory Standards (NCCLS) methods (18, 19) . Brucella agar supplemented with hemin, vitamin K 1 , and 5% laked sheep blood was the basal medium used for anaerobic species and for Eikenella corrodens and Weeksella zoohelcum. Mueller-Hinton agar was used for staphylococci, and Mueller-Hinton agar supplemented with 5% sheep blood was used for the remainder of the organisms. Serial dilutions of antimicrobial agents were reconstituted according to the manufacturers' instructions on the day of the test and added to the agar media at various concentrations.
The agar plates were inoculated with a Steers replicator (Craft Machine Inc., Chester, Pa.). An inoculum of 10 4 CFU per spot was used for aerobes, and 10 5 CFU per spot was used for E. corrodens and anaerobes. E. corrodens, W. zoohelcum, and streptococci were incubated in 5% CO 2 , anaerobic bacteria were incubated in an anaerobic chamber for 48 h; and other organisms were incubated in ambient air at 37°C for 24 h prior to examination.
The The activities of gatifloxacin and the other agents tested against the bite wound isolates are shown in Table 1 . Gatifloxacin was active at Յ0.125 g/ml against all aerobic bite wound isolates, with the exception of some streptococci (MIC at which 90% of the isolates were inhibited [MIC 90 ], 1 g/ml; range, Ͻ0.03 to 2 g/ml). All six fluoroquinolones tested were active at Յ0.125 g/ml against all 148 Pasteurella isolates (eight species and three P. multocida subspecies).
The other aerobic genera and species tested were also susceptible to Յ0.125 g of gatifloxacin per ml, with the exception of streptococci, which varied by species: all Streptococcus mitis isolates were susceptible to Յ0.5 g/ml, 10 isolates of Streptococcus mutans and other species were susceptible to Յ1 g/ml, but 2 g/ml was required for inhibition of 1 of 4 isolates of Streptococcus intermedius.
Gatifloxacin was active against Bacteroides tectum (MIC 90 , 0.125 g/ml), Prevotella heparinolytica (MIC 90 , 0.125 g/ml), other Prevotella and Porphyromonas spp. (MIC 90 , 0.25 g/ml), g Fusobacterium species include (n) Fusobacterium gonidiaformans (1), Fusobacterium necrophorum (1), Fusobacterium russii (6) , and other fusobacteria (2) . h Porphyromonas species include (n) Porphyromonas cangingivalis (2), Porphyromonas canoris (5), Porphyromonas gingivalis (8) , Porphyromonas circumdentaria (2), and Porphyromonas macacae (8) .
i Prevotella species include (n) Prevotella bivia (3), Prevotella buccae (2), Prevotella intermedia (4), Prevotella denticola (1), Prevotella loeschii (1), Prevotella melaninogenica (2), and Prevotella zoogleoformans (2) .
j Peptostreptococcus species include (n) Peptostreptococcus anaerobius (6) , Peptostreptococcus asaccharolyticus (1), Peptostreptococcus magnus (1), and other Peptostreptococcus species (2). and peptostreptococci (MIC 90 , 0.5 g/ml). Gatifloxacin was slightly more active against Prevotella spp. than was trovafloxacin but otherwise was generally equivalent to trovafloxacin. Consistent with our findings, Ednie et al. (5) , using an unspecified NCCLS agar dilution method, reported gatifloxacin to have an MIC 50 and an MIC 90 of 0.5 and 1 g/ml, respectively, for 55 peptostreptococcal isolates. Schaumann et al. (22) reported an MIC 90 of 0.25 g/ml for peptostreptococci by using a broth microdilution method, which may account for the disparity.
Fusobacterium species (MIC 50 and MIC 90 , Ն8 g/ml], including Fusobacterium nucleatum (MIC 50 , 0.25 g/ml; MIC 90 , Ն8 g/ml), were sometimes resistant to gatifloxacin as well as to the other quinolones. Ednie et al. (5) reported gatifloxacin to have an MIC 50 and an MIC 90 of 0.5 g/ml for F. nucleatum and Fusobacterium mortiferum, 0.5 and 1 g/ml, respectively, for Fusobacterium necrophorum, and 4 g/ml for Fusobacterium varium. Schaumann et al. (22) tested 17 Fusobacterium species by a broth microdilution method and reported an MIC 90 of 8 g/ml.
Erwin et al. (6) studied Fusobacterium species by an unspecified NCCLS agar dilution method and reported an MIC 90 of 0.19 g/ml for gatifloxacin, which they noted to be more active than trovafloxacin. In contrast, we found that trovafloxacin had an MIC 90 of Յ4 g/ml against fusobacteria; this value was generally within one dilution of the gatifloxacin results. Also in contrast to our findings, Wexler et al. (27) and Spangler et al. (23) noted trovafloxacin MIC 90 s of 0.5 and 0.25 mg/liter, respectively, for F. nucleatum and MIC 90 s of 0.5 and 1.0 g/ml, respectively, for other Fusobacterium spp. Since the same methods were used by us and by Wexler et al. (27) , the reason for this disparity is unclear, except that we studied veterinary isolates recovered from human infections, while Wexler et al. used human isolates recovered from other sources. The different medium used by Spangler et al. (23) , supplemented Wilkins-Chalgren agar, may account for some variation.
Gatifloxacin appears to be more active than older quinolones against a spectrum of pathogens isolated from human and animal bite wounds and merits further clinical evaluation.
